CA19-9/Sialyl Lewis A Antibody (CA19.9/1390R)

Immunohistochemistry-Paraffin: CA19-9/Sialyl Lewis A Antibody (CA19.9/1390R) [NBP2-53220] - CA19-9/Sialyl Lewis A antibody staining in human ductal carcinoma. IHC-P image submitted by a verified customer review.

Immunohistochemistry-Paraffin: CA19-9/Sialyl Lewis A Antibody (CA19.9/1390R) [NBP2-53220] - Human Gastric Carcinoma stained with CA19-9 Recombinant Rabbit Monoclonal Antibody (CA19.9/1390R).

• Reactivity: Hu
• Applications: IHC
• Clone: CA19.9/1390R
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: 0.2 mg/ml

CA19-9/Sialyl Lewis A Antibody (CA19.9/1390R) Summary

• Description: 200ug/ml of antibody purified by Protein A column. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA and azide at 1 mg/ml.(NBP2-54585)
  
  Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Purified human CA19-9/Sialyl Lewis A protein
• Localization: Cytoplasmic
• Marker: GI Tumor Marker
• Specificity: CA19-9, a carbohydrate epitope expressed on a high MW (400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This monoclonal antibody is excellent for staining of formalin-fixed, paraffin-embedded tissues.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 5-10 ug/ml
• Application Notes: Immunohistochemistry (Formalin-fixed): 5-10ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
  Optimal dilution for a specific application should be determined.
• Theoretical MW: 400 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 10 mM PBS with 0.05% BSA
• Preservative: 0.05% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: Protein A purified

Alternate Names for CA19-9/Sialyl Lewis A Antibody (CA19.9/1390R)

• CA 19-9
• CA19-9

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CA19-9/Sialyl Lewis A Antibody (NBP2-53220)(1)

Publication using NBP2-53220

• Ghaddar B, Biswas A, Harris C Et al. Tumor microbiome links cellular programs and immunity in pancreatic cancer Cancer Cell 2022-10-11 [PMID: 36220074]
  
  Details:
  Citation using the Azide and BSA Free version of this antibody.

Review for CA19-9/Sialyl Lewis A Antibody (NBP2-53220) (1)

Average Rating: 5

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer IHC-P Human 10/11/2021

Summary

• Application: Immunohistochemistry-Paraffin
• Sample Tested: Ductal carcinoma
• Species: Human
• Lot: CA19.9/1390R

Comments

• Comments: Tissue sections were deparaffinized. Antigen retrieval was done enzymatically. Incubated O/N in 4 C with the primary antibody (1:200 dilution), followed by secondary antibody incubation (1:300 dilution).